Ozempic safety and effectiveness after launch in type 2 diabetes
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tracks how Ozempic works and whether it stays safe for people with type 2 diabetes in everyday clinic care in Korea. You join because your doctor decides you should start Ozempic, and the study mainly monitors outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 19 years old when you sign consent
- Your doctor has decided you should start commercial Ozempic for type 2 diabetes before joining
- You must be able to sign informed consent and do required study steps
- You have never taken Ozempic before (and are not currently taking it)
- You do not have a known allergy or suspected serious reaction to Ozempic
- If you are able to get pregnant: you must not be pregnant or breastfeeding, and you must use reliable birth control
- You can understand study instructions and participate (no major language or thinking/decision barriers)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks the safety and effectiveness of Rybelsus (oral semaglutide) in people with type 2 diabetes who are starting the medication as part of their usual care. It helps confirm that the drug works well and is safe in everyday practice.
This study tests a new medication called semaglutide (similar to Ozempic) in people with type 2 diabetes who are already taking metformin. It aims to see if this medication improves blood sugar control and may also help with weight loss.
This study looks at how well people in China stick with taking Ozempic (a once-weekly injection) compared to other diabetes medicines. It helps researchers understand if this medicine is easier to keep taking long-term.
This trial tests an investigational pill called icovamenib for people with type 2 diabetes who are already on Ozempic but still have high blood sugar. The goal is to see if adding icovamenib helps lower blood sugar more safely.
This trial tests whether semaglutide can lower heart disease risks in children with extreme obesity. It aims to improve weight and heart health over time.
This study watches how Wegovy (semaglutide) works and its side effects when given by doctors to patients with obesity or overweight in South Korea. It is not testing a new drug, but collecting information from routine care.
Hear when a new Diabetes Mellitus, Type 2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.